Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes

NCT07896109 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07896109 Recruiting Phase 1 121 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07896109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Recruiting, started October 2026. Interventional study, Phase 1, 121 participants (estimated). Lead sponsor Novo Nordisk A/S; Germany. Primary measures: Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs); Multiple ascending dose (MAD): Number of TEAEs.

How it compares

1,044 similar trials: same condition (Diabetes Mellitus, Type 2) and phase

Enrollment

This trial
121
Middle half
24 to 56
Median
35
Trials with a value
1,038

Months from start to completion

This trial
21.1
Middle half
3 to 14
Median
6.5
Trials with a value
998

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
934
Posted results or a linked paper 36% 371 of 1,044 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Official title
A Phase 1 Randomised, Double-blinded, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of NNC9836-0001 Administered to Healthy Participants and Participants With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Recruiting
Start date
October 22, 2026
Completion date
July 26, 2028
Enrollment
121 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
25 Years
Maximum age
69 Years
Healthy volunteers
Yes
Study type
Interventional
Sites
1
Countries
Germany
Lead sponsor
Novo Nordisk A/S

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
NNC9836-0001 Experimental NNC9836-0001
Show registry wording

Participants will receive NNC9836-0001 subcutaneously.

Placebo Placebo comparator Placebo (NaCl)
Show registry wording

Participants will receive placebo subcutaneously.

Primary endpoints

Registered primary outcome measures; 2 primary.

Registered primary endpoints
Measure Time frame
Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs) From dosing (day 1) until week 26
Show registry wording

Measured as events.

Multiple ascending dose (MAD): Number of TEAEs From dosing (day 1) to week 34
Show registry wording

Measured as events.

Lead sponsor's other trials

Novo Nordisk A/S, most recent start first.

Similar trials

Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.